2022 KIA Niro 2 EV Electricity · WF22 ABO

The vehicle currently maintains a clean roadworthiness status, evidenced by the most recent pass on 25 March 2026 at 62,074 miles. This latest test recorded no defects, suggesting a stable mechanical condition following the previous year's intervention. The brief failure recorded on 12 March 2025 at 56,489 miles appears to be a procedural anomaly or an immediate rectification, as the vehicle successfully passed the same day without any listed advisories. This pattern indicates that the vehicle has been kept in a high state of repair, with no evidence of chronic mechanical neglect or recurring component failure. Accumulating 62,074 miles over a four-year period results in an average of approximately 15,500 miles per annum, which sits well above the typical usage profile for a private passenger vehicle. This high-mileage history suggests the car has spent significant time in motorway or arterial road environments rather than short, stop-start urban cycles. While the electric drivetrain in the Kia Niro generally experiences less wear than internal combustion equivalents, this level of usage necessitates a closer look at high-mileage consumables that are not always captured during a standard MOT test. Prospective buyers should focus their physical inspection on the condition of the suspension bushes, track rod ends, and wheel bearings, as these components endure the most stress during high-mileage operation. Although the MOT record is currently clear, check the brake discs for signs of surface corrosion or pitting, which can occur if the regenerative braking system is used exclusively, leading to under-use of the friction brakes. Verify the tyre tread depth and ensure the sidewalls remain free of impact damage, as the high mileage indicates the vehicle has likely covered a diverse range of road surfaces. The lack of structural or mechanical advisories throughout the history provides a solid baseline, but a thorough check of the undercarriage for any signs of road debris impact remains a prudent step.